Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04712097 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
A Phase 3 study of Relapsed or Refractory Follicular Lymphoma, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
- 20
- Study locations
NCT04712097: Active Phase 3 study of Relapsed or Refractory Follicular Lymphoma, sponsored by Hoffmann-La Roche.
NCT04712097 is a Phase 3 study of Relapsed or Refractory Follicular Lymphoma that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 478 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04712097, a Phase 3 study of Relapsed or Refractory Follicular Lymphoma, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
- DRUG Rituximab
- DRUG Lenalidomide
- DRUG Tociluzumab
Study Locations (20)
New York
- NYU Long Island Hospital - Mineola
- NYU Langone Ambulatory Care Center - New York
- Montefiore Medical Center - Montefiore Medical Park - The Bronx
- Montefiore Medical Center - The Bronx
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc - Fort Wayne
- Investigative Clinical Research of Indiana, LLC - Noblesville
Michigan
- University of Michigan Health System - Ann Arbor
- Cancer & Hematology Center of West Michigan - Grand Rapids
North Carolina
- Duke University Medical Center - Durham
- Wake Forest Univ Health Svcs - Winston-Salem
Texas
- Baylor University Medical Center - Dallas
- MD Anderson Cancer Center - Houston
California
- City of Hope Comprehensive Cancer Center - Duarte
Georgia
- Winship Cancer Institute - Atlanta
Maryland
- Johns Hopkins Uni - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 3 |
What the registry record for NCT04712097 still lists
NCT04712097 is an interventional study that assigns participants to a tested intervention. The registered 478 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (38% lower).
The record links to 1 condition, with Relapsed or Refractory Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Mosunetuzumab is the first listed.
NCT04712097 names 20 study sites across 13 states, led by New York, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT04712097 about?
NCT04712097 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma". This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior system...
What is the current status of trial NCT04712097?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2021-10-27. Estimated completion is 2029-12-31.
What conditions does trial NCT04712097 study?
This clinical trial studies the following conditions: Relapsed or Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT04712097?
The interventions under investigation include: Mosunetuzumab (DRUG), Rituximab (DRUG), Lenalidomide (DRUG), Tociluzumab (DRUG).
Who is sponsoring clinical trial NCT04712097?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04712097 being conducted?
This trial has 20 study locations across California, Georgia, Indiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04712097's enrollment target sits among peer trials
478 805th of 2000 higher than 1,195 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI